You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, hepatitis, serious respiratory and cardiovascular conditions, cancer and inflammation.
Our portfolio of marketed products includes a number of category firsts, including the only complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high risk adults.
Collaborations of all kinds – with partners in science, academia, business and local communities – are central to our work. Partnerships enhance our ability to develop innovative medicines and deliver them to people as efficiently as possible.
Gilead was founded in 1987 in Foster City, California. Over the past 25 years, we have grown to become one of the world’s largest biopharmaceutical companies, with approximately 5,000 employees across four continents.
2012 Interactive Annual Report